Bithionol
 inhibits ovarian cancer cell growth In Vitro
 - studies on mechanism(s) of action

The rate of disease recurrance is very high in ovarian cancer patients due to drug resistance. If even one cancer cell survives chemotherapy, it may multiply and cause a relapse. Ayyagari and Brard are looking for new treatment options for ovarian cancer patients, and they're looking in FDA approved drugs to speed things along. Bithionol is already being used as an antiparasitic, a second-line treatment for helminths. Biothionol has shown promising anticancer activity before in breast cancers, melanoma and others, but there is still some discussion yet on its anticancer mode of action. This paper investigates a few of the possible mechanisms including cell cycle arrest, apoptosis initiation, reactive oxygen species generation and autotaxin inhibition.

Read more here: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922745/